By Fineline Cube Japan-based Shionogi & Co., Ltd has submitted a New Drug Application (NDA) to the National Medical Products Administration (NMPA) in China for its oral antiviral drug S-217622, developed through a joint venture with Ping An Life Insurance Company under the name Ping An-Shionogi Co., Ltd.
Drug Profile
S-217622 is an oral antiviral agent administered once daily for five days. It suppresses the growth of the SARS-CoV-2 virus by selectively inhibiting the 3CL protease. The drug has demonstrated the ability to rapidly reduce viral load, improve respiratory and fever-related symptoms, and is well tolerated by patients.-Fineline Info & Tech